# Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

> **NCT02367859** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 1 (actual)

## Conditions studied

- Ameloblastoma
- BRAF Gene Mutation

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02367859
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2018-11-05
- **Final completion:** 2019-06-26
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367859, "Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02367859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*